Wu 6-marker phage peptide panel for Lung Cancer
Aliases:This biomarker is also known as:
The six-phage peptide detector stands out as a promising diagnostic biomarker for NSCLC. The peptide panel could be used to diagnose non-small cell lung cancer and to differentiate between non-small cell lung cancer and chronic obstructive pulmonary diseases. One of the six phage peptides shows 100% homology to olfactomedin 1
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
The sixÃƒÆ'Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬ÃƒÂ¢Ã¢â€šÂ¬Ã…â€œphage peptide detector could be used to diagnose NSCLC at early stage and discriminate NSCLC and chronic obstructive pulmonary diseases. Chemotherapy significantly reduced the seroreactivity of the sixÃƒÆ'Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬ÃƒÂ¢Ã¢â€šÂ¬Ã…â€œphage peptide clones. The sixÃƒÆ'Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬ÃƒÂ¢Ã¢â€šÂ¬Ã…â€œphage peptide detector can be used as a novel method for noninvasive diagnosis and screening of NSCLC in high-risk populations. However, it is unlikely to be used as biomarkers for indicating the relapse of NSCLC after chemotherapy.
The six-phage peptide detector was able to discriminate between NSCLC patients and healthy controls with a sensitivity and specificity of >92%, and had similar validity for indicating NSCLC at early stage. The seroreactivity of the six phage peptides was significantly higher in the NSCLC patients than in those with chemotherapy and the COPD patients, respectively.
No associated resources found.